Tirzepatide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Tirzepatide — GLP-1R / GIPR Dual Agonist (“Twincretin”)

Tirzepatide is a synthetic 39-amino acid peptide engineered to simultaneously activate two key incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Its dual-receptor profile positions it between the well-established selectivity of semaglutide and the triple-agonist complexity of retatrutide, making it one of the most pharmacologically distinctive compounds available for metabolic research. Structurally based on the native GIP sequence with a C20 fatty diacid moiety enabling albumin binding, tirzepatide achieves a half-life consistent with once-weekly dosing protocols.

Why Dual Incretin Agonism Matters

What makes tirzepatide particularly notable in research is not just that it hits two receptors — it’s how it hits them. Tirzepatide is an imbalanced agonist: it binds the GIP receptor with affinity comparable to native GIP, while engaging the GLP-1 receptor with notably weaker affinity. This pharmacological asymmetry is thought to be a feature, not a limitation — full GIPR engagement appears to potentiate GLP-1R signaling in ways that exceed what selective GLP-1R agonism alone can achieve, while keeping GI tolerability more manageable at escalating doses.

The synergistic interaction between GIP and GLP-1 receptor activation is a primary subject of active research — co-activation produces insulin and glucagonostatic responses that exceed what either pathway delivers independently.

Research Applications

Tirzepatide is used in studies examining:

• Dual incretin synergy and its contribution to metabolic outcomes beyond GLP-1R agonism alone
• Comparative efficacy against selective GLP-1R agonists (semaglutide) and triple agonists (retatrutide)
• Beta-cell function preservation and insulin sensitivity improvement in metabolic models
• Body composition and adipose tissue dynamics under dual receptor activation
• Hepatic lipid accumulation and MASH/MASLD pathway research
• Dose-response relationships in imbalanced receptor engagement protocols
• GIP receptor biology and its role in energy homeostasis — historically understudied, now of significant interest

Specifications

Reconstitution

Tirzepatide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 10mg vial + 2mL BAC water = 5mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Due to its imbalanced dual-receptor activity and long half-life, tirzepatide protocols employ gradual dose escalation to characterize the individual receptor contributions at each stage and allow for observation of GI-related receptor adaptation.

Typical titration framework:

• Starting dose: 0.5–1mg per administration
• Escalation: Increase by 0.5–1mg every 2–4 weeks as tolerated
• Frequency: Once weekly (consistent with its long half-life profile)
• Study duration: 8–16 weeks for body composition and metabolic endpoints

Commonly observed effects in research models:

• GI-related (receptor-mediated, typically transient): Nausea, vomiting, diarrhea, constipation, reduced appetite, early satiety — dose-dependent in incidence and generally most pronounced during escalation phases
• Metabolic: Reduced caloric intake, fluid balance shifts, electrolyte considerations at sustained higher doses
• Other: Injection site irritation, headache, mild dizziness at escalation intervals

Research Stacks

Tirzepatide is commonly paired in research settings with:

• Semaglutide — Semaglutide is a mono-selective GLP-1 receptor agonist; researchers pair with Tirzepatide’s dual GLP-1/GIP agonism to isolate the incremental contribution of GIP receptor co-engagement to outcomes observed with GLP-1 signaling alone.
• CJC-1295 No DAC / Ipamorelin — CJC-1295 No DAC and Ipamorelin stimulate GH secretion via GHRH and ghrelin receptors; pairing with Tirzepatide’s incretin receptor activity allows researchers to study interactions between the GH/IGF-1 axis and dual GLP-1/GIP receptor signaling in metabolic research models.
• MOTS-c — MOTS-c activates AMPK to enhance peripheral insulin sensitivity and mitochondrial efficiency; combining with Tirzepatide’s GLP-1/GIP-mediated pancreatic and central signaling provides a model for studying convergent central and cellular mechanisms of metabolic regulation.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.